Moreover, the combined use of autophagy inhibitors and PD-1 or CTLA-4 immune checkpoint blocking monoclonal Abs (mAb) increases Cytotoxic T lymphocytes (CTL) infiltration in murine models of PDAC and non-small cell lung cancer (NSCLC), indicating a promising therapeutic approach for these tumors [23]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.